BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27338823)

  • 1. Ameliorating effect of Kalpaamruthaa on altered energy metabolism in BCR-ABL
    Palanivelu S; Dhanasekeran S; Khan HB; Panchanadham ST
    Chin J Integr Med; 2016 Jun; ():. PubMed ID: 27338823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of energy metabolism in leukemic mice treated by a siddha drug--Semecarpus anacardium Linn. nut milk extract.
    Sugapriya D; Shanthi P; Sachdanandam P
    Chem Biol Interact; 2008 May; 173(1):43-58. PubMed ID: 18358458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells.
    De Rosa V; Monti M; Terlizzi C; Fonti R; Del Vecchio S; Iommelli F
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31252559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
    He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
    Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.
    Alvarez-Calderon F; Gregory MA; Pham-Danis C; DeRyckere D; Stevens BM; Zaberezhnyy V; Hill AA; Gemta L; Kumar A; Kumar V; Wempe MF; Pollyea DA; Jordan CT; Serkova NJ; Graham DK; DeGregori J
    Clin Cancer Res; 2015 Mar; 21(6):1360-72. PubMed ID: 25547679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
    Zeng Y; Graner MW; Thompson S; Marron M; Katsanis E
    Blood; 2005 Mar; 105(5):2016-22. PubMed ID: 15374884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
    Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
    Zhao F; Mancuso A; Bui TV; Tong X; Gruber JJ; Swider CR; Sanchez PV; Lum JJ; Sayed N; Melo JV; Perl AE; Carroll M; Tuttle SW; Thompson CB
    Oncogene; 2010 May; 29(20):2962-72. PubMed ID: 20228846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristic of two mouse bcr-abl-transformed cell lines: I. General properties of the cells.
    Sobotkova E; Ludvíková V; Petrácková M; Dusková M; Smetana K; Jelínek F; Marinov I; Vonka V
    Folia Biol (Praha); 2005; 51(1):12-8. PubMed ID: 15783087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia.
    Zeng Y; Graner MW; Feng H; Li G; Katsanis E
    Int J Cancer; 2004 Jun; 110(2):251-9. PubMed ID: 15069690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
    Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
    Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
    Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
    Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
    Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
    J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
    Skorski T; Nieborowska-Skorska M; Nicolaides NC; Szczylik C; Iversen P; Iozzo RV; Zon G; Calabretta B
    Proc Natl Acad Sci U S A; 1994 May; 91(10):4504-8. PubMed ID: 8183938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of
    Yang L; Qiu Q; Tang M; Wang F; Yi Y; Yi D; Yang Z; Zhu Z; Zheng S; Yang J; Pei H; Zheng L; Chen Y; Gou L; Luo L; Deng X; Ye H; Hu Y; Niu T; Chen L
    Clin Cancer Res; 2019 Dec; 25(24):7527-7539. PubMed ID: 31439580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells.
    Shinohara H; Kumazaki M; Minami Y; Ito Y; Sugito N; Kuranaga Y; Taniguchi K; Yamada N; Otsuki Y; Naoe T; Akao Y
    Cancer Lett; 2016 Feb; 371(1):1-11. PubMed ID: 26607903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel imatinib-upregulated long noncoding RNA plays a critical role in inhibition of tumor growth induced by Abl oncogenes.
    Ma Y; Guo G; Li T; Wen F; Yang J; Chen B; Wang X; Chen JL
    Mol Cancer; 2022 Jan; 21(1):5. PubMed ID: 34980123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
    Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S
    Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.